Grants and Contributions:
Title:
Development of new class of add-on to statin lipid-lowering therapeutics for patients at high cardiovascular risk.
Agreement Number:
925778
Agreement Value:
$414,000.00
Agreement Date:
Apr 1, 2019 - Mar 31, 2021
Description:
This project will support the preclinical development of newly patented cholesterol-lowering therapeutics to demonstrate their efficacy, additive effect to statins and safety in full support to initiate human clinical studies.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H1T 1C8
Reference Number:
172-2019-2020-Q1-925778
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
785597493
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 70,000 dollars.
Amendment Date
Feb 17, 2021
Recipient's Legal Name:
Monogenic Pharmaceutiques inc.
Federal Riding Name:
Hochelaga
Federal Riding Number:
24028
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: